secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001606498-23-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos Q2 sales $169.4M, adjusted EPS $0.24; FY2023 adjusted EPS guidance $1.05-$1.15
--------------------------------------------------------------------------------

- Q2 net sales $169.4M (-0.9% YoY); net loss $4.3M vs net income $4.8M a year ago.
- Adjusted diluted EPS $0.24 vs $0.26; adjusted EBITDA flat at $22.9M.
- Closed Diros Technologies acquisition (RFA) in July; recorded $72.3M impairment on Respiratory Health divestiture.
- UK NICE recommends RFA for osteoarthritic knee pain, potentially improving Pain Management reimbursement.
- FY2023 outlook: adjusted EPS $1.05-$1.15, adjusted gross margin >59%, H2 organic growth low single-digit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000063/0001606498-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000063/avns-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001606498-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer